Skip to content

60 DEGREES PHARMACEUTICALS, INC.: 10-Q filed 2025-11-13

What 60 DEGREES PHARMACEUTICALS, INC. reported in its quarterly report filed 2025-11-13 (fiscal Q3 2025): 49 published measures, 151 facts as tagged in accession 0001554855-25-002032.

This filing

Form
10-Q (quarterly report)
Filed
2025-11-13
Fiscal period
fiscal Q3 2025
Accession
0001554855-25-002032 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All 60 DEGREES PHARMACEUTICALS, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2025-09-306,689,344USD
At 2024-12-315,759,345USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2025-09-302,342,386USD
At 2024-12-311,804,339USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2025-09-304,430,220USD
At 2024-12-314,035,600USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2025-09-304,115,779USD
At 2024-12-311,659,353USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2025-07-01 to 2025-09-30-2,316,324USD92
2025-01-01 to 2025-09-30-5,926,599USD273
2024-07-01 to 2024-09-30-2,159,785USD92
2024-01-01 to 2024-09-30-5,902,070USD274

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2025-01-01 to 2025-09-30-5,156,566USD273
2024-01-01 to 2024-09-30-4,009,871USD274

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

PeriodValueUnitDays
2025-01-01 to 2025-09-3060,000USD273
2024-01-01 to 2024-09-30103,773USD274

Revenue

Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.

PeriodValueUnitDays
2025-07-01 to 2025-09-30437,602USD92
2025-01-01 to 2025-09-30702,086USD273
2024-07-01 to 2024-09-30135,293USD92
2024-01-01 to 2024-09-30365,939USD274

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2025-01-01 to 2025-09-305,979,077USD273
2024-01-01 to 2024-09-307,052,598USD274

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2025-01-01 to 2025-09-301,625,347USD273
2024-01-01 to 2024-09-30-1,887,016USD274

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2025-09-30-46,454,556USD
At 2024-12-31-40,527,957USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2025-07-01 to 2025-09-303,675,407shares92
2025-01-01 to 2025-09-302,152,682shares273
2024-07-01 to 2024-09-30488,654shares92
2024-01-01 to 2024-09-30287,529shares274

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

PeriodValueUnitDays
2025-07-01 to 2025-09-303,675,407shares92
2025-01-01 to 2025-09-30488,654shares273
2024-07-01 to 2024-09-302,152,682shares92
2024-01-01 to 2024-09-30287,529shares274

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2025-07-01 to 2025-09-30-0.66USD/shares92
2025-01-01 to 2025-09-30-2.92USD/shares273
2024-07-01 to 2024-09-30-4.65USD/shares92
2024-01-01 to 2024-09-30-21.74USD/shares274

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

PeriodValueUnitDays
2025-07-01 to 2025-09-30-0.66USD/shares92
2025-01-01 to 2025-09-30-4.65USD/shares273
2024-07-01 to 2024-09-30-2.92USD/shares92
2024-01-01 to 2024-09-30-21.74USD/shares274

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

PeriodValueUnitDays
2025-07-01 to 2025-09-30250USD92
2025-01-01 to 2025-09-301,813USD273
2024-07-01 to 2024-09-30250USD92
2024-01-01 to 2024-09-30751USD274

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2025-09-30227,752USD
At 2024-12-31149,808USD

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2025-07-01 to 2025-09-30-2,325,525USD92
2025-01-01 to 2025-09-30-5,841,228USD273
2024-07-01 to 2024-09-30-2,118,692USD92
2024-01-01 to 2024-09-30-7,649,890USD274

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2025-09-306,309,209USD
At 2024-12-315,386,277USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2025-09-302,197,394USD
At 2024-12-311,657,220USD

Net current accounts receivable

Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.

PeriodValueUnitDays
At 2025-09-30674,036USD
At 2024-12-31486,748USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2025-07-01 to 2025-09-302,316,397USD92
2025-01-01 to 2025-09-306,272,931USD273
2024-07-01 to 2024-09-302,155,116USD92
2024-01-01 to 2024-09-307,792,318USD274

Net inventory

Inventory carrying amount after applicable valuation and LIFO reserves. It does not establish realizable selling proceeds or inventory turnover without other inputs.

PeriodValueUnitDays
At 2025-09-30527,004USD
At 2024-12-31442,764USD

Gross profit

Revenue less the costs directly attributed to the goods or services sold. It precedes other operating expenses and is not net income.

PeriodValueUnitDays
2025-07-01 to 2025-09-30-100,088USD92
2025-01-01 to 2025-09-3041,073USD273
2024-07-01 to 2024-09-3023,606USD92
2024-01-01 to 2024-09-3099,251USD274

Cost of revenue

Costs attributed to goods produced and sold and services provided during the period. This is not the sum of every operating expense.

PeriodValueUnitDays
2025-07-01 to 2025-09-30537,690USD92
2025-01-01 to 2025-09-30661,013USD273
2024-07-01 to 2024-09-30111,687USD92
2024-01-01 to 2024-09-30266,688USD274

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2025-07-01 to 2025-09-30809,777USD92
2025-01-01 to 2025-09-301,467,283USD273
2024-07-01 to 2024-09-30940,063USD92
2024-01-01 to 2024-09-304,372,571USD274

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2025-09-304,104,469shares
At 2024-12-31566,908shares

Cash including restricted cash

Cash, cash equivalents and restricted cash as reported in the cash flow reconciliation. Restricted amounts are not freely available, so this is not the same as unrestricted cash.

PeriodValueUnitDays
At 2025-09-304,115,779USD
At 2024-12-311,659,353USD
At 2024-09-303,300,688USD
At 2023-12-312,142,485USD

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2025-09-3041,172,888USD
At 2024-12-3134,860,590USD

Accumulated other comprehensive income or loss

Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.

PeriodValueUnitDays
At 2025-09-30144,039USD
At 2024-12-31135,471USD

Total equity including noncontrolling interests

Equity including the portion attributable to noncontrolling interests. It is larger than or equal to parent stockholders equity and is not market capitalization.

PeriodValueUnitDays
At 2025-09-304,346,958USD
At 2025-06-302,345,704USD
At 2025-03-314,028,889USD
At 2024-12-313,955,006USD
At 2024-09-305,962,847USD
At 2024-06-302,959,384USD
At 2024-03-317,125,478USD
At 2023-12-314,798,096USD

Long-term debt

Long-term borrowings under this concept, which can include the current portion depending on presentation. It is not total liabilities and may exclude leases and other obligations.

PeriodValueUnitDays
At 2025-09-30150,000USD

Gross property, plant and equipment

Cost of property, plant and equipment before accumulated depreciation. Historical cost does not indicate current value or replacement cost.

PeriodValueUnitDays
At 2025-09-30403,437USD
At 2024-12-31299,241USD

Accumulated depreciation on property, plant and equipment

Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.

PeriodValueUnitDays
At 2025-09-30175,685USD
At 2024-12-31149,433USD

Net intangible assets excluding goodwill

Intangible assets other than goodwill after amortization and impairment. Internally developed intangibles are usually not recognized, so this understates what a company relies on.

PeriodValueUnitDays
At 2025-09-30152,383USD
At 2024-12-31157,084USD

Other noncurrent assets

Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.

PeriodValueUnitDays
At 2025-09-30152,383USD
At 2024-12-31223,260USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

PeriodValueUnitDays
At 2025-09-30992,390USD
At 2024-12-311,068,940USD

Pre-tax income or loss from continuing operations

Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.

PeriodValueUnitDays
2025-07-01 to 2025-09-30-2,316,786USD92
2025-01-01 to 2025-09-30-5,927,454USD273
2024-07-01 to 2024-09-30-2,160,248USD92
2024-01-01 to 2024-09-30-5,905,988USD274

Profit or loss including noncontrolling interests

Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.

PeriodValueUnitDays
2025-07-01 to 2025-09-30-2,317,036USD92
2025-01-01 to 2025-09-30-5,929,267USD273
2025-04-01 to 2025-06-30-1,734,930USD91
2025-01-01 to 2025-03-31-1,877,301USD90
2024-07-01 to 2024-09-30-2,160,498USD92
2024-01-01 to 2024-09-30-5,906,739USD274
2024-04-01 to 2024-06-30-4,174,226USD91
2024-01-01 to 2024-03-31427,985USD91

Comprehensive income or loss

Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.

PeriodValueUnitDays
2025-07-01 to 2025-09-30-2,315,094USD92
2025-01-01 to 2025-09-30-5,918,031USD273
2024-07-01 to 2024-09-30-2,155,382USD92
2024-01-01 to 2024-09-30-5,898,424USD274

Net income available to common stockholders

Net income after preferred dividends and similar adjustments, the numerator for basic earnings per share. It can be lower than reported net income.

PeriodValueUnitDays
2025-07-01 to 2025-09-30-2,443,191USD92
2025-01-01 to 2025-09-30-6,290,991USD273
2024-07-01 to 2024-09-30-2,271,953USD92
2024-01-01 to 2024-09-30-6,250,757USD274

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2025-07-01 to 2025-09-301,506,620USD92
2025-01-01 to 2025-09-304,805,648USD273
2024-07-01 to 2024-09-301,215,053USD92
2024-01-01 to 2024-09-303,419,747USD274

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

PeriodValueUnitDays
2025-01-01 to 2025-09-3028,155USD273
2024-01-01 to 2024-09-306,277USD274

Depreciation, depletion and amortization

Combined depreciation, depletion and amortization for the period. A noncash allocation of asset cost, not a measure of maintenance spending.

PeriodValueUnitDays
2025-07-01 to 2025-09-3012,225USD92
2025-01-01 to 2025-09-3028,155USD273
2024-07-01 to 2024-09-304,334USD92
2024-01-01 to 2024-09-306,277USD274

Amortization of intangible assets

Amortization recognized on finite-lived intangible assets. It follows acquisition accounting and does not indicate the intangibles are losing usefulness at that rate.

PeriodValueUnitDays
2025-07-01 to 2025-09-3010,605USD92
2025-01-01 to 2025-09-3031,150USD273
2024-07-01 to 2024-09-3010,325USD92
2024-01-01 to 2024-09-3028,004USD274

Nonoperating interest expense

Interest expense presented outside operating results. It differs from total interest expense when some borrowing cost is classified as operating or capitalized.

PeriodValueUnitDays
2025-07-01 to 2025-09-301,708USD92
2025-01-01 to 2025-09-304,719USD273
2024-07-01 to 2024-09-301,467USD92
2024-01-01 to 2024-09-306,490USD274

Other nonoperating income or expense

Other income or expense outside operations under this concept. The composition is filer-specific and can include one-time items.

PeriodValueUnitDays
2025-07-01 to 2025-09-3031,550USD92
2025-01-01 to 2025-09-3074,938USD273
2024-07-01 to 2024-09-3016,623USD92
2024-01-01 to 2024-09-3067,358USD274

Change in accounts receivable

The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.

PeriodValueUnitDays
2025-01-01 to 2025-09-30187,288USD273
2024-01-01 to 2024-09-3092,490USD274

Change in inventories

The cash flow adjustment for the change in inventories during the period. A positive value under this concept means inventory grew and reduced operating cash flow.

PeriodValueUnitDays
2025-01-01 to 2025-09-30328,922USD273
2024-01-01 to 2024-09-30-14,133USD274

Inspect the source

Entity
60 DEGREES PHARMACEUTICALS, INC. / CIK 0001946563
Captured
2026-09-21T17:41:45.368Z
SEC response SHA-256
b95fff66e7a953f292c25a6ce30bc53c9746adb7dec7916bb5971972be8b9ae4

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001946563.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))